A61K31/60

Hair removal admixture with wax, antiseptic, analgesic, moisturizing oil, and chemical depilatory: Hair removal chemical composite/creamy wax.
20220401346 · 2022-12-22 ·

Hair removal Chemical composite/creamy wax. This waxing mixture is used to easily remove unwanted hair. To those seeking quick removal of hair without much pain, discomfort, sores, and the like. Helps to calm the skin during the hair removal procedure. Good for those seeking to do waxing by themselves, and doesn't need professional supervision. Quick hair removal waxing chemical composition, a waxing admixture for the 21st century. Less pain, more hair removal.

Therapies and methods to treat TLR2-mediated diseases and disorders

The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.

Therapies and methods to treat TLR2-mediated diseases and disorders

The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.

COMPOSITION FOR THE MAKING OF AN EMULSIFIABLE TRIPHASIC FORMULATION, AND KIT FOR THE USE OF SUCH COMPOSITION
20220395437 · 2022-12-15 ·

The invention relates to a composition for the making of an emulsifiable triphasic formulation, which consists of a liquid biphasic composition and a powder solid phase, wherein said liquid biphasic composition consists of a hydrophilic phase and a lipophilic phase. The triphasic emulsifiable composition obtained from the combination of the biphasic liquid composition and the solid powder phase by a kit of the invention is particularly suitable for the use in the clinical-dermatological and/or cosmetological fields.

COMPOSITION FOR THE MAKING OF AN EMULSIFIABLE TRIPHASIC FORMULATION, AND KIT FOR THE USE OF SUCH COMPOSITION
20220395437 · 2022-12-15 ·

The invention relates to a composition for the making of an emulsifiable triphasic formulation, which consists of a liquid biphasic composition and a powder solid phase, wherein said liquid biphasic composition consists of a hydrophilic phase and a lipophilic phase. The triphasic emulsifiable composition obtained from the combination of the biphasic liquid composition and the solid powder phase by a kit of the invention is particularly suitable for the use in the clinical-dermatological and/or cosmetological fields.

TOPICAL FORMULATIONS OF CYCLOOXYGENASE INHIBITORS AND THEIR USE
20220378729 · 2022-12-01 · ·

A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

TOPICAL FORMULATIONS OF CYCLOOXYGENASE INHIBITORS AND THEIR USE
20220378729 · 2022-12-01 · ·

A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF

The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.

DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF

The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.

BLENDED FORMULATIONS
20220370353 · 2022-11-24 ·

The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.